Skip to main content

Table 1 Baseline characteristics of patients

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

  LEN monotherapy
(n = 39)
LEN combination
(n = 72)
LEN + PD1
(n = 30)
LEN + HAIF/TACE
(n = 24)
LEN + PD1 + HAIF/TACE
(n = 16)
Age (Median ± SE) 50 ± 13.3 51 ± 11.9 50.5 ± 10.6 55 ± 13.1 50 ± 12.8
Gender (Male/Female) 37/2 66/6 28/2 23/1 13/3
BCLC stage (A/B/C) 6/11/22 11/14/47 5/5/20 3/5/16 3/3/10
HBV infection (Yes/No) 33/6 65/7 28/2 22/2 13/3
AFP (ng/ml) (< 400/> 400) 24/15 33/39 15/15 9/15 8/8
Median follow-up (week) 44.7 45.1 48.9 45.2 36.4
Child-Pugh (A/B) 7/32 7/65 4/26 2/24 16/16
  1. AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HAIF, hepatic arterial infusion with drug filtration; HBV, hepatitis B virus; LEN, lenvatinib; PD1, programmed cell death protein-1; TACE, transcatheter arterial chemoembolization